Barclays Maintains Overweight on CVS Health, Raises Price Target to $108

Benzinga Newsdesk www.benzinga.com Positive 80.9%

Neg 0% Neu 0% Pos 80.9%

Barclays analyst Andrew Mok maintains CVS Health (NYSE:CVS) with a Overweight and raises the price target from $106 to $108.